RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BridgeBio Pharma Stock

BridgeBio Pharma Employees 2025

BridgeBio Pharma Employees

385

Ticker

BBIO

ISIN

US10806X1028

WKN

A2PLX7

In 2025, BridgeBio Pharma employed 385 people, a 0% change from the 385 number of employees in the previous year.

BridgeBio Pharma Aktienanalyse

What does BridgeBio Pharma do?

BridgeBio Pharma Inc. is a US biotech company founded in 2015. The company is based in Palo Alto, California and specializes in researching and developing medications for rare diseases. BridgeBio's business model is based on a pipeline of rare diseases that have little or no existing treatment options. The company identifies, finances, and operates individual independent subsidiary companies with the goal of developing precision medicines for rare and genetic diseases. An important element of BridgeBio's business strategy is strategic collaboration with academic institutions and other companies to share research and development expertise. BridgeBio has various subsidiary companies, each specializing in the development of medications for a specific genetic disease. These include Eidos Therapeutics, QED Therapeutics, PellePharm, Navire Pharma, Origin Biosciences, CoA Therapeutics, Calcilytix Therapeutics, Phoenix Tissue Repair, and MyoKardia. Eidos Therapeutics is constantly searching for therapies for transthyretin-mediated amyloidosis (ATTR), a rare cardiovascular disease caused by the buildup of amyloid proteins in various parts of the body. The first FDA-approved eprodisate therapy became available in Japan in 2005, making Eidos Therapeutics one of the most promising subsidiary companies of BridgeBio. QED Therapeutics specializes in developing therapies for Gorlin syndrome and medulloblastoma, a type of brain tumor. PellePharm aims to develop a topical therapy for Gorlin syndrome that can be used to control and treat tumors and non-tumorous skin changes. Navire Pharma explores specific kinases that influence cell growth and cell death signaling pathways to identify healing methods for cancer patients. Calcilytix Therapeutics focuses on discovering a treatment solution for chronic kidney diseases, with a main focus on stopping or reducing the loss of kidney function. Overall, BridgeBio is dedicated to the development of precision medicines designed to combat the underlying genetic causes of rare diseases. The company also advances the field of precision medicine and works closely with doctors and patients to improve the diagnosis of rare diseases and optimize patient care. In 2019, BridgeBio Pharma announced a strategic partnership with the Pharmaceutical Research and Manufacturers of America (PhRMA). The goal of this collaboration is to improve awareness of rare diseases and create better access to new medications. BridgeBio hopes that the partnership will accelerate the development of therapies for rare diseases. In conclusion, BridgeBio Pharma Inc. is an innovative biotech company specializing in the development of precision medicines for the treatment of rare genetic diseases. With a business model based on collaboration with subsidiary companies and strategic partners, BridgeBio Pharma Inc. aims to revolutionize the treatment and cure of patients with rare genetic diseases. BridgeBio Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining BridgeBio Pharma's Employee Base

BridgeBio Pharma's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding BridgeBio Pharma's operational capacity and future potential.

Year-to-Year Comparison

Assessing BridgeBio Pharma's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

BridgeBio Pharma's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in BridgeBio Pharma’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about BridgeBio Pharma stock

How many employees does BridgeBio Pharma have this year?

BridgeBio Pharma has 385 undefined employees this year.

How many employees did BridgeBio Pharma have compared to the previous year?

Compared to the previous year, BridgeBio Pharma had 0% more employees.

What impact did the number of employees have on the company BridgeBio Pharma?

The number of employees has a direct impact on the efficiency and productivity of BridgeBio Pharma. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of BridgeBio Pharma?

The number of employees can also have an impact on investors of BridgeBio Pharma, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of BridgeBio Pharma affect the company?

An increase in equity of BridgeBio Pharma can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in BridgeBio Pharma's equity affect the company?

A reduction in equity of BridgeBio Pharma can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of BridgeBio Pharma?

Some factors that can influence the equity of BridgeBio Pharma include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of BridgeBio Pharma so important for investors?

The equity of BridgeBio Pharma is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at BridgeBio Pharma influence the company?

The number of employees at BridgeBio Pharma can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at BridgeBio Pharma evolved in recent years?

In recent years, the number of employees at BridgeBio Pharma has changed by 0.

How many employees does BridgeBio Pharma currently have?

BridgeBio Pharma currently has 385 undefined employees.

Why is the number of employees important for investors of BridgeBio Pharma?

The number of employees is important for investors of BridgeBio Pharma as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can BridgeBio Pharma take to change the number of employees?

To change the number of employees, BridgeBio Pharma can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does BridgeBio Pharma pay?

Over the past 12 months, BridgeBio Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BridgeBio Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of BridgeBio Pharma?

The current dividend yield of BridgeBio Pharma is .

When does BridgeBio Pharma pay dividends?

BridgeBio Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BridgeBio Pharma?

BridgeBio Pharma paid dividends every year for the past 0 years.

What is the dividend of BridgeBio Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BridgeBio Pharma located?

BridgeBio Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von BridgeBio Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BridgeBio Pharma from 1/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/6/2025.

When did BridgeBio Pharma pay the last dividend?

The last dividend was paid out on 1/6/2025.

What was the dividend of BridgeBio Pharma in the year 2024?

In the year 2024, BridgeBio Pharma distributed 0 USD as dividends.

In which currency does BridgeBio Pharma pay out the dividend?

The dividends of BridgeBio Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BridgeBio Pharma

Our stock analysis for BridgeBio Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BridgeBio Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.